Last Price
30.34
Today's Change
+0.165 (0.54%)
Day's Change
30.03 - 31.53
Trading Volume
68,820
Overview
Market Cap
978 Million
Shares Outstanding
32 Million
Avg Volume
378,425
Avg Price (50 Days)
36.66
Avg Price (200 Days)
35.50
PE Ratio
12.97
EPS
2.34
Earnings Announcement
20-Feb-2025
Previous Close
30.18
Open
30.48
Day's Range
30.034 - 31.53
Year Range
24.606 - 42.287
Trading Volume
68,884
Price Change Highlight
1 Day Change
0.55%
5 Day Change
-8.10%
1 Month Change
-20.14%
3 Month Change
-11.53%
6 Month Change
-8.85%
Ytd Change
-2.83%
1 Year Change
20.85%
3 Year Change
51.65%
5 Year Change
65.91%
10 Year Change
146.91%
Max Change
146.91%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Description:
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
12
Apps
Top Articles
1
CEO Morning Brief
US Ordered TSMC to Halt Shipments of Chips for AI to China — Reuters
2
3
CEO Morning Brief
Dogecoin Outperforms Bitcoin as Trump Spurs Crypto Speculation
4
CEO Morning Brief
5
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
